

**Biocon Limited** 

20th KM Hosur Road Electronics City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423

CIN: L24234KA1978PLC003417

www.biocon.com

Date: 13th February 2023

To,	To,			
The Secretary	The Secretary			
BSE Limited	National Stock Exchange of India Limited			
Department of Corporate Services	Corporate Communication Department			
Phiroze Jeejeebhoy Towers,	Exchange Plaza, Bandra Kurla Complex			
Dalal Street, Mumbai – 400 001	Mumbai – 400 050			
Scrip Code - 532523	Scrip Symbol - Biocon			

Dear Sirs,

## Certificate pursuant to SEBI Circular no. SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021

In terms of Chapter XVII of the SEBI Circular no. SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021, on Operational Circular for issue and listing of Non-convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper, as amended from time to time, please find enclosed a quarterly certificate confirming the use of Commercial Paper proceeds and adherence to other listing conditions, for the quarter ended 31st December, 2022.

We request you to kindly take the above certificate on record.

Thanking you.

Yours faithfully,

For Biocon Limited

Mayank Verma

**Company Secretary and Compliance Officer** 

Membership No.: ACS 18776

Encl: As above



To,	To,			
The Secretary	The Secretary			
BSE Limited	National Stock Exchange of India Limited			
Department of Corporate Services	Corporate Communication Department			
Phiroze Jeejeebhoy Towers,	Exchange Plaza, Bandra Kurla Complex			
Dalal Street, Mumbai – 400 001	Mumbai – 400 050			
Scrip Code - 532523	Scrip Symbol - Biocon			

REF NO: ISIN CODE: As Per Annexure !

Maturity Value of CP: As Per Annexure I

Maturity Date of CP: As Per Annexure I

With reference to the above-mentioned Commercial Paper issued by us, it is hereby certified that:

- 1. The CPs were issued for the purposes mentioned in Annexure I and the CP proceeds were utilized for purposes disclosed therein and the Company is in adherence to other listing conditions as mentioned in the application for listing.
- 2. The other conditions of the offer document and the CP issuance directions are adhered to.
- 3. The asset classification of fund-based facilities from bank/Financial Institutions continues to be "Standard"
- 4. There has been no material change in our financial status which may adversely affect the credit rating of the Commercial Paper.
- The total issuance of CPs during the calendar year up to the quarter ended Dec 2022 was Rs. 2250 Crores.

For Biocon Limited

Indranil Sen (Chief Financial Officer)

Date: 13th February 2023

Place: - Bangalore



## Annexure I

Issuer Name	Date of CP issue	ISIN No.	Maturity Value in Rs. Cr	Maturity Date of CP	Units	End Use of Fund
Biocon Limited	23/11/2022	INE376CG14016	2250	22/02/2023	45000	General Corporate Purpose (mezzanine financing) covering equity investment/ loan into subsidiaries

